Current perspectives on the health risks associated with the consumption of advanced glycation end products: Recommendations for dietary management

Diabetes, Metabolic Syndrome and Obesity

Volumn 8, Issue , 2015, Pages 415-426

  Palimeri, Sotiria ^a   Palioura, Eleni ^a   Diamanti Kandarakis, Evanthia ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

AGEs; Dietary glycotoxins; Dietary restriction; MSR 1; PCOS; RAGE

Indexed keywords

3 BENZYLOXYCARBONYLMETHYL 4 METHYL THIAZOL 3 IUM BROMIDE; ADVANCED GLYCATION END PRODUCT; ALAGEBRIUM; ANTIHYPERTENSIVE AGENT; AST 120; BISPHOSPHONIC ACID DERIVATIVE; GLYCOTOXIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; N (2 ACETAMIDOETHYL)HYDROZINECARBOXIMIDAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PIGMENT EPITHELIUM DERIVED FACTOR; PYRIDOXAMINE; TETRAHYDROLIPSTATIN; TOXIN; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; CANCER RISK; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; COGNITIVE DEFECT; COOKING; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIET RESTRICTION; DIETARY INTAKE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; EVIDENCE BASED MEDICINE; EYE DISEASE; HEALTH HAZARD; HUMAN; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INTESTINE ABSORPTION; KIDNEY FAILURE; LIVER DISEASE; LIVER DYSFUNCTION; MALIGNANT NEOPLASTIC DISEASE; NEUROLOGIC DISEASE; NONHUMAN; OBESITY; OUTCOME ASSESSMENT; OVARY POLYCYSTIC DISEASE; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; REPRODUCTIVE TOXICITY; REVIEW; TOXICOKINETICS; URINARY EXCRETION;

EID: 84940752283     PISSN: None     EISSN: 11787007     Source Type: Journal    
DOI: 10.2147/DMSO.S63089     Document Type: Review

References (108)

1. Vlassara H, Palace MR. Diabetes and advanced glycation endproducts. J Intern Med. 2002;251(2):87–101
2. Cerami C, Founds H, Nicholl I, et al. Tobacco smoke is a source of toxic reactive glycation products. Proc Natl Acad Sci U S A. 1997; 94(25):13915–13920
3. Goldberg T, Cai W, Peppa M, et al. Advanced glycoxidation end products in commonly consumed foods. J Am Diet Assoc. 2004;104(8): 1287–1291
4. Vlassara H, Uribarri J, Cai W, Striker G. Advanced glycation end product homeostasis: exogenous oxidants and innate defenses. Ann N Y Acad Sci. 2008;1126:46–52
5. Vlassara H, Striker GE. Advanced glycation endproducts in diabetes and diabetic complications. Endocrinol Metab Clin North Am. 2013;42(4):697–719
6. Ahmed N. Advanced glycation endproducts – role in pathology of diabetic complications. Diabetes Res Clin Pract. 2005;67(1):3–21
7. Wu CH, Huang SM, Lin JA, Yen GC. Inhibition of advanced glycation endproduct formation by foodstuffs. Food Funct. 2011;2(5): 224–234
8. Bierhaus A, Stern DM, Nawroth PP. RAGE in inflammation: a new therapeutic target? Curr Opin Investig Drugs. 2006;7(11):985–991
9. Yonekura H, Yamamoto Y, Sakurai S, Watanabe T, Yamamoto H. Roles of the receptor for advanced glycation endproducts in diabetes-induced vascular injury. J Pharmacol Sci. 2005;97(3):305–311
10. Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation. 2006;114(6):597–605
11. Stern D, Yan SD, Yan SF, Schmidt AM. Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings. Adv Drug Deliv Rev. 2002;54(12):1615–1625
12. Koschinsky T, He CJ, Mitsuhashi T, et al. Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci U S A. 1997;94(12): 6474–6479
13. Vlassara H, Cai W, Crandall J, et al. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci U S A. 2002;99(24):15596–15601
14. Uribarri J, Peppa M, Cai W, et al. Dietary glycotoxins correlate with circulating advanced glycation end product levels in renal failure patients. Am J Kidney Dis. 2003;42(3):532–538
15. Uribarri J, Peppa M, Cai W, et al. Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients. J Am Soc Nephrol. 2003;14(3):728–731
16. Henle T. AGEs in foods: do they play a role in uremia? Kidney Int Suppl. 2003;(84):S145–S147
17. Erbersdobler HF, Faist V. Metabolic transit of Amadori products. Nahrung. 2001;45(3):177–181
18. Gugliucci A, Bendayan M. Renal fate of circulating advanced glycated end products (AGE): evidence for reabsorption and catabolism of AGE-peptides by renal proximal tubular cells. Diabetologia. 1996;39(2):149–160
19. Monnier VM, Sell DR, Nagaraj RH, et al. Maillard reaction-mediated molecular damage to extracellular matrix and other tissue proteins in diabetes, aging, and uremia. Diabetes. 1992;41 Suppl 2:36–41
20. Niwa T, Katsuzaki T, Momoi T, et al. Modification of beta 2 m with advanced glycation end products as observed in dialysis-related amyloidosis by 3-DG accumulating in uremic serum. Kidney Int. 1996;49(3):861–867
21. Bucala R, Makita Z, Vega G, et al. Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci U S A. 1994;91(20):9441–9445
22. Jensen LJ, Østergaard J, Flyvbjerg A. AGE-RAGE and AGE Cross-link interaction: important players in the pathogenesis of diabetic kidney disease. Horm Metab Res. 2005;37 Suppl 1:26–34
23. Saito A, Takeda T, Sato K, et al. Significance of proximal tubular metabolism of advanced glycation end products in kidney diseases. Ann N Y Acad Sci. 2005;1043:637–643
24. Vlassara H. Advanced glycation in health and disease: role of the modern environment. Ann N Y Acad Sci. 2005;1043:452–460
25. Vlassara H, Striker LJ, Teichberg S, Fuh H, Li YM, Steffes M. Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci U S A. 1994;91(24): 11704–11708
26. Smedsrød B, Melkko J, Araki N, Sano H, Horiuchi S. Advanced glycation end products are eliminated by scavenger-receptor mediated endocytosis in hepatic sinusoidal Kupffer and endothelial cells. Biochem J. 1997;322(2):567–573
27. Matsumoto K, Sano H, Nagai R, et al. Endocytic uptake of advanced glycation end products by mouse liver sinusoidal endothelial cells is mediated by a scavenger receptor distinct from the macrophage scavenger receptor class A. Biochem J. 2000;352(1):233–240
28. Hansen B, Svistounov D, Olsen R, Nagai R, Horiuchi S, Smedsrød B. Advanced glycation end products impair the scavenger function of rat hepatic sinusoidal endothelial cells. Diabetologia. 2002;45(10): 1379–1388
29. Santos JC, Valentim IB, de Araújo OR, Ataide Tda R, Goulart MO. Development of nonalcoholic hepatopathy: contributions of oxidative stress and advanced glycation end products. Int J Mol Sci. 2013;14(10):19846–19866
30. Goh SY, Cooper ME. Clinical review: The role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab. 2008;93(4):1143–1152
31. Sandu O, Song K, Cai W, Zheng F, Uribarri J, Vlassara H. Insulin resistance and type 2 diabetes in high-fat-fed mice are linked to high glycotoxin intake. Diabetes. 2005;54(8):2314–2319
32. Cai W, Ramdas M, Zhu L, Chen X, Striker GE, Vlassara H. Oral advanced glycation endproducts (AGEs) promote insulin resistance and diabetes by depleting the antioxidant defenses AGE receptor-1 and sirtuin 1. Proc Natl Acad Sci U S A. 2012;109(39):15888–15893
33. Uribarri J, Cai W, Ramdas M, et al. Restriction of advanced glycation end products improves insulin resistance in human type 2 diabetes: potential role of AGER1 and SIRT1. Diabetes Care. 2011;34(7):1610–1616.
34. Negrean M, Stirban A, Stratmann B, et al. Effects of low- and highadvanced glycation endproduct meals on macro- and microvascular endothelial function and oxidative stress in patients with type 2 diabetes mellitus. Am J Clin Nutr. 2007;85(5):1236–1243
35. Stirban A, Negrean M, Götting C, et al. Dietary advanced glycation endproducts and oxidative stress: in vivo effects on endothelial function and adipokines. Ann N Y Acad Sci. 2008;1126:276–279
36. Miyata T, Kurokawa K, van Ypersele de Strihou C. Relevance of oxidative and carbonyl stress to long-term uremic complications. Kidney Int Suppl. 2000;76:S120–S125
37. Raj DS, Choudhury D, Welbourne TC, Levi M. Advanced glycation end products: a Nephrologist’s perspective. Am J Kidney Dis. 2000;35(3):365–380
38. Busch M, Franke S, Müller A, et al. Potential cardiovascular risk factors in chronic kidney disease: AGEs, total homocysteine and metabolites, and the C-reactive protein. Kidney Int. 2004;66(1):338–347
39. Tan AL, Forbes JM, Cooper ME. AGE, RAGE, and ROS in diabetic nephropathy. Semin Nephrol. 2007;27(2):130–143
40. Chung AC, Zhang H, Kong YZ, et al. Advanced glycation end-products induce tubular CTGF via TGF-beta-independent Smad3 signaling. J Am Soc Nephrol. 2010;21(2):249–260
41. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003;41(1):1–12
42. Tanaka S, Avigad G, Brodsky B, Eikenberry EF. Glycation induces expansion of the molecular packing of collagen. J Mol Biol. 1988;203(2):495–505
43. Haitoglou CS, Tsilibary EC, Brownlee M, Charonis AS. Altered cellular interactions between endothelial cells and nonenzymatically glucosylated laminin/type IV collagen. J Biol Chem. 1992;267(18): 12404–12407
44. Gu L, Hagiwara S, Fan Q, et al. Role of receptor for advanced glycation end-products and signalling events in advanced glycation end-p roductinduced monocyte chemoattractant protein-1 expression in differentiated mouse podocytes. Nephrol Dial Transplant. 2006;21(2):299–313
45. Palimeri S, Palioura E, Piperi C, et al. Additive effects of dietary glycotoxins and androgen excess on the kidney of a female rat model. Alex J Med. Epub
46. Sebeková K, Kupcová V, Schinzel R, Heidland A. Markedly elevated levels of plasma advanced glycation end products in patients with liver cirrhosis – amelioration by liver transplantation. J Hepatol. 2002;36(1):66–71
47. Yagmur E, Tacke F, Weiss C, et al. Elevation of Nepsilon-(carboxymethyl) lysine-modified advanced glycation end products in chronic liver disease is an indicator of liver cirrhosis. Clin Biochem. 2006;39(1):39–45
48. Hyogo H, Yamagishi S, Iwamoto K, et al. Elevated levels of serum advanced glycation end products in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol. 2007;22(7):1112–1119
49. Sato T, Wu X, Shimogaito N, Takino J, Yamagishi S, Takeuchi M. Effects of high-AGE beverage on RAGE and VEGF expressions in the liver and kidneys. Eur J Nutr. 2009;48(1):6–11
50. Cai W, He JC, Zhu L, et al. Reduced oxidant stress and extended lifespan in mice exposed to a low glycotoxin diet: association with increased AGER1 expression. Am J Pathol. 2007;170(6):1893–1902
51. Patel R, Baker SS, Liu W, et al. Effect of dietary advanced glycation end products on mouse liver. PLoS One. 2012;7(4):e35143
52. Diamanti-Kandarakis E, Piperi C, Kalofoutis A, Creatsas G. Increased levels of serum advanced glycation end-products in women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 2005;62(1):37–43
53. Diamanti-Kandarakis E, Piouka A, Livadas S, et al. Anti-mullerian hormone is associated with advanced glycosylated end products in lean women with polycystic ovary syndrome. Eur J Endocrinol. 2009;160(5):847–853
54. Diamanti-Kandarakis E, Katsikis I, Piperi C, et al. Increased serum advanced glycation end-products is a distinct finding in lean women with polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf). 2008;69(4):634–641
55. Diamanti-Kandarakis E, Piperi C, Patsouris E, et al. Immunohistochemical localization of advanced glycation end-products (AGEs) and their receptor (RAGE) in polycystic and normal ovaries. Histochem Cell Biol. 2007;127(6):581–589
56. Diamanti-Kandarakis E, Piperi C, Korkolopoulou P, et al. Accumulation of dietary glycotoxins in the reproductive system of normal female rats. J Mol Med (Berl). 2007;85(12):1413–1420
57. Kandaraki E, Chatzigeorgiou A, Piperi C, et al. Reduced ovarian glyoxalase-I activity by dietary glycotoxins and androgen excess: a causative link to polycystic ovarian syndrome. Mol Med. 2012;18: 1183–1189
58. Tantalaki E, Piperi C, Livadas S, et al. Impact of dietary modification of advanced glycation end products (AGEs) on the hormonal and metabolic profile of women with polycystic ovary syndrome (PCOS). Hormones (Athens). 2014;13(1):65–73
59. Chatzigeorgiou A, Kandaraki E, Piperi C, et al. Dietary glycotoxins affect scavenger receptor expression and the hormonal profile of female rats. J Endocrinol. 2013;218(3):331–337
60. Diamanti-Kandarakis E, Chatzigeorgiou A, Papageorgiou E, Koundouras D, Koutsilieris M. Advanced glycation end-products and insulin signaling in granulosa cells. Exp Biol Med. Epub 2015 May 7
61. Boutzios G, Livadas S, Piperi C, et al. Polycystic ovary syndrome offspring display increased oxidative stress markers comparable to gestational diabetes offspring. Fertil Steril. 2013;99(3):943–950
62. Salahuddin P, Rabbani G, Khan RH. The role of advanced glycation end products in various types of neurodegenerative disease: a therapeutic approach. Cell Mol Biol Lett. 2014;19(3):407–437
63. Cai W, Uribarri J, Zhu L, et al. Oral glycotoxins are a modifiable cause of dementia and the metabolic syndrome in mice and humans. Proc Natl Acad Sci U S A. 2014;111(13):4940–4945
64. Kandarakis SA, Piperi C, Topouzis F, Papavassiliou AG. Emerging role of advanced glycation-end products (AGEs) in the pathobiology of eye diseases. Prog Retin Eye Res. 2014;42:85–102
65. Kandarakis SA, Piperi C, Moschonas DP, Korkolopoulou P, Papalois A, Papavassiliou AG. Dietary glycotoxins induce RAGE and VEGF up-regulation in the retina of normal rats. Exp Eye Res. 2015;137:1–10
66. Sharaf H, Matou-Nasri S, Wang Q, et al. Advanced glycation endproducts increase proliferation, migration and invasion of the breast cancer cell line MDA-MB-231. Biochim Biophys Acta. 2015;1852(3): 429–441
67. Rodriguez-Teja M, Gronau JH, Breit C, et al. AGE-modified basement membrane cooperates with Endo180 to promote epithelial cell invasiveness and decrease prostate cancer survival. J Pathol. 2015;235(4): 581–592
68. Takino J, Yamagishi S, Takeuchi M. Cancer malignancy is enhanced by glyceraldehyde-derived advanced glycation end-products. J Oncol. 2010;2010:739852
69. van Heijst JW, Niessen HW, Hoekman K, Schalkwijk CG. Advanced glycation end products in human cancer tissues: detection of Nepsilon-(carboxymethyl)lysine and argpyrimidine. Ann N Y Acad Sci. 2005;1043:725–733
70. Foster D, Spruill L, Walter KR, et al. AGE metabolites: a biomarker linked to cancer disparity? Cancer Epidemiol Biomarkers Prev. 2014;23(10):2186–2191
71. Jiao L, Weinstein SJ, Albanes D, et al. Evidence that serum levels of the soluble receptor for advanced glycation end products are inversely associated with pancreatic cancer risk: a prospective study. Cancer Res. 2011;71(10):3582–3589
72. Jiao L, Taylor PR, Weinstein SJ, et al. Advanced glycation end products, soluble receptor for advanced glycation end products, and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2011;20(7): 1430–1438
73. Grote VA, Nieters A, Kaaks R, et al. The associations of advanced glycation end products and its soluble receptor with pancreatic cancer risk: a case-control study within the prospective EPIC Cohort. Cancer Epidemiol Biomarkers Prev. 2012;21(4):619–628.
74. Turner DP. Advanced glycation end-products: a biological consequence of lifestyle contributing to cancer disparity. Cancer Res. 2015;75(10):1925–1929
75. Hofmann SM, Dong HJ, Li Z, et al. Improved insulin sensitivity is associated with restricted intake of dietary glycoxidation products in the db/db mouse. Diabetes. 2002;51(7):2082–2089
76. Zheng F, He C, Cai W, Hattori M, Steffes M, Vlassara H. Prevention of diabetic nephropathy in mice by a diet low in glycoxidation products. Diabetes Metab Res Rev. 2002;18(3):224–237
77. Vlassara H, Striker GE. AGE restriction in diabetes mellitus: a paradigm shift. Nat Rev Endocrinol. 2011;7(9):526–539
78. Pouillart P, Mauprivez H, Ait-Ameur L, et al. Strategy for the study of the health impact of dietary Maillard products in clinical studies: the example of the ICARE clinical study on healthy adults. Ann N Y Acad Sci. 2008;1126:173–176
79. Vlassara H, Cai W, Goodman S, et al. Protection against loss of innate defenses in adulthood by low advanced glycation end products (AGE) intake: role of the antiinflammatory AGE receptor-1. J Clin Endocrinol Metab. 2009;94(11):4483–4491
80. Birlouez-Aragon I, Saavedra G, Tessier FJ, et al. A diet based on high-heat-treated foods promotes risk factors for diabetes mellitus and cardiovascular diseases. Am J Clin Nutr. 2010;91(5):1220–1226
81. Kellow NJ, Savige GS. Dietary advanced glycation end-product restriction for the attenuation of insulin resistance, oxidative stress and endothelial dysfunction: a systematic review. Eur J Clin Nutr. 2013;67(3):239–248
82. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science. 1986;232(4758):1629–1632
83. Hammes HP, Brownlee M, Edelstein D, Saleck M, Martin S, Federlin K. Aminoguanidine inhibits the development of accelerated diabetic retinopathy in the spontaneous hypertensive rat. Diabetologia. 1994;37(1):32–35
84. Soulis-Liparota T, Cooper M, Papazoglou D, Clarke B, Jerums G. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes. 1991;40(10):1328–1334
85. Nishizawa Y, Wada R, Baba M, Takeuchi M, Hanyu-Itabashi C, Yagihashi S. Neuropathy induced by exogenously administered advanced glycation end-products in rats. J Diabetes Investig. 2010;1(1–2):40–49
86. Forbes JM, Soulis T, Thallas V, et al. Renoprotective effects of a novel inhibitor of advanced glycation. Diabetologia. 2001;44(1):108–114
87. Wilkinson-Berka JL, Kelly DJ, Koerner SM, et al. ALT-946 and aminoguanidine, inhibitors of advanced glycation, improve severe nephropathy in the diabetic transgenic (mREN-2)27 rat. Diabetes. 2002;51(11):3283–3289
88. Cheng G, Wang LL, Long L, et al. Beneficial effects of C36, a novel breaker of advanced glycation endproducts cross-links, on the cardiovascular system of diabetic rats. Br J Pharmacol. 2007;152(8): 1196–1206
89. Okamoto T, Yamagishi S, Inagaki Y, et al. Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. FASEB J. 2002;16(14):1928–1930
90. Stitt A, Gardiner TA, Alderson NL, et al. The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes. 2002;51(9):2826–2832
91. Degenhardt TP, Alderson NL, Arrington DD, et al. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int. 2002;61(3):939–950
92. Vasan S, Zhang X, Zhang X, et al. An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature. 1996;382(6588): 275–278
93. Candido R, Forbes JM, Thomas MC, et al. A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res. 2003;92(7):785–792
94. Coughlan MT, Forbes JM, Cooper ME. Role of the AGE crosslink breaker, alagebrium, as a renoprotective agent in diabetes. Kidney Int Suppl. 2007;(106):S54–S60
95. Kass DA, Shapiro EP, Kawaguchi M, et al. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation. 2001;104(13):1464–1470
96. Little WC, Zile MR, Kitzman DW, Hundley WG, O’Brien TX, Degroof RC. The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fail. 2005;11(3):191–195
97. Aldini G, Vistoli G, Stefek M, et al. Molecular strategies to prevent, inhibit, and degrade advanced glycoxidation and advanced lipoxidation end products. Free Radic Res. 2013;47 Suppl 1:93–137
98. Win MT, Yamamoto Y, Munesue S, et al. Regulation of RAGE for attenuating progression of diabetic vascular complications. Exp Diabetes Res. 2012;2012:894605
99. Yamagishi S, Nakamura K, Matsui T, Ueda S, Fukami K, Okuda S. Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications. Expert Opin Investig Drugs. 2008;17(7):983–996
100. Park L, Raman KG, Lee KJ, et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med. 1998;4(9):1025–1031
101. Bucciarelli LG, Wendt T, Qu W, et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation. 2002;106(22):2827–2835
102. Barile GR, Pachydaki SI, Tari SR, et al. The RAGE axis in early diabetic retinopathy. Invest Ophthalmol Vis Sci. 2005;46(8):2916–2924.
103. Kaji Y, Usui T, Ishida S, et al. Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products. Invest Ophthalmol Vis Sci. 2007; 48(2):858–865
104. Li F, Drel VR, Szabó C, Stevens MJ, Obrosova IG. Low-dose poly(ADP-ribose) polymerase inhibitor-containing combination therapies reverse early peripheral diabetic neuropathy. Diabetes. 2005;54(5): 1514–1522
105. Pacher P, Liaudet L, Soriano FG, Mabley JG, Szabó E, Szabó C. The role of poly(ADP-ribose) polymerase activation in the development of myocardial and endothelial dysfunction in diabetes. Diabetes. 2002;51(2):514–521
106. Ueda S, Yamagishi S, Takeuchi M, et al. Oral adsorbent AST-120 decreases serum levels of AGEs in patients with chronic renal failure. Mol Med. 2006;12(7–8):180–184
107. Diamanti-Kandarakis E, Katsikis I, Piperi C, Alexandraki K, Panidis D. Effect of long-term orlistat treatment on serum levels of advanced glycation end-products in women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 2007;66(1):103–109
108. Piperi C, Adamopoulos C, Dalagiorgou G, Diamanti-Kandarakis E, Papavassiliou AG. Crosstalk between advanced glycation and endoplasmic reticulum stress: emerging therapeutic targeting for metabolic diseases. J Clin Endocrinol Metab. 2012;97(7): 2231–2242.